DrugFeb 14, 2018
Mckesson Packaging Services Megestrol Acetate Oral Suspension, USP 400 mg/ 10mL recall — FDA D-0338-2018
Subpotent Drug: Out of specification for assay (stability testing)
Class IIIFDA: TerminatedMckesson Packaging Services
Recall history in this database
Classification mix: Class III: 8, Class II: 1.
DrugSep 13, 2017
Mckesson Packaging Services Propafenone Hydrochloride tablets, 150 mg recall — FDA D-1128-2017
Failed moisture limits: Out of specification for moisture content.
Class IIIFDA: TerminatedMckesson Packaging Services
DrugMay 3, 2017
Mckesson Packaging Services Donepezil HCl tablets, 10mg recall — FDA D-0680-2017
Supotent: Out of Specification result for assay test during routine stability testing.
Class IIIFDA: TerminatedMckesson Packaging Services
DrugMar 15, 2017
Mckesson Packaging Services Aspirin Chewable Tablets, 81 mg, (NSAID*) recall — FDA D-0513-2017
Presence of Foreign Substance: foreign material found in the bulk inventory.
Class IIFDA: CompletedMckesson Packaging Services
DrugOct 5, 2016
Mckesson Packaging Services Xanax (Alprazolam) USP, CIV, 0.5 mg tablets , 10 x 10 blister recall — FDA D-1527-2016
Labeling: Missing Label-Primary packaging label (i.e. blister card) is blank and contains no product information (e.g. product name, strength, lot number, expiry).
Class IIIFDA: TerminatedMckesson Packaging Services
DrugOct 5, 2016
Mckesson Packaging Services Lansoprazole Delayed-Release Capsules, USP, 30 mg recall — FDA D-1550-2016
Labeling: Label mix-up. The inner packaging was properly labeled Omeprazole DR 40mg Capsules, but the outer secondary packaging was mislabeled Lansoprazole Delayed-Release 30mg Capsules.
Class IIIFDA: TerminatedMckesson Packaging Services
DrugMar 26, 2014
McKesson Packaging Services Venlafaxine Hydrochloride, Extended Release Capsules, 150 mg recall — FDA D-1167-2014
Failed Dissolution Specification: Out of Specification dissolution results at 12 month interval.
Class IIIFDA: TerminatedMcKesson Packaging Services
DrugOct 10, 2012
McKesson Packaging Services buPROPion Hydrochloride Extended-Release Tablets (XL), 300 mg recall — FDA D-002-2013
Failed USP Dissolution Test Requirements: Possible out-of-specification dissolution results at the 8 hour stability testing point.
Class IIIFDA: TerminatedMcKesson Packaging Services
DrugOct 10, 2012
McKesson Packaging Services buPROPion Hydrochloride Extended-Release Tablets (XL), 150 mg recall — FDA D-001-2013
Failed USP Dissolution Test Requirements: Possible out-of-specification dissolution results at the 8 hour stability testing point.
Class IIIFDA: TerminatedMcKesson Packaging Services
Understanding this recall history
This page summarizes recall records in which the official source identifies Mckesson Packaging Services as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.